These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1231 related items for PubMed ID: 28536008

  • 1. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK, Mondal G, Kumar V, Kattel K, Mahato RI.
    Cancer Lett; 2017 Aug 28; 402():1-8. PubMed ID: 28536008
    [Abstract] [Full Text] [Related]

  • 2. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
    Karaca M, Dutta R, Ozsoy Y, Mahato RI.
    Mol Pharm; 2016 Jun 06; 13(6):1822-32. PubMed ID: 26981724
    [Abstract] [Full Text] [Related]

  • 3. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
    Mondal G, Almawash S, Chaudhary AK, Mahato RI.
    Mol Pharm; 2017 Sep 05; 14(9):3121-3133. PubMed ID: 28719220
    [Abstract] [Full Text] [Related]

  • 4. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
    Ma C, Huang T, Ding YC, Yu W, Wang Q, Meng B, Luo SX.
    Int J Clin Exp Pathol; 2015 Sep 05; 8(6):6533-9. PubMed ID: 26261532
    [Abstract] [Full Text] [Related]

  • 5. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z, Zhao N, Cui J, Wu H, Xiong J, Peng T.
    Cell Oncol (Dordr); 2020 Feb 05; 43(1):123-136. PubMed ID: 31713003
    [Abstract] [Full Text] [Related]

  • 6. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
    Mondal G, Kumar V, Shukla SK, Singh PK, Mahato RI.
    Biomacromolecules; 2016 Jan 11; 17(1):301-13. PubMed ID: 26626700
    [Abstract] [Full Text] [Related]

  • 7. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K.
    Cancer Lett; 2017 Sep 10; 403():296-304. PubMed ID: 28687352
    [Abstract] [Full Text] [Related]

  • 8. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
    Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH.
    Cancer Prev Res (Phila); 2012 Mar 10; 5(3):355-64. PubMed ID: 22086681
    [Abstract] [Full Text] [Related]

  • 9. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A, Afgar A, Mahmoodzadeh H, Radfar JE, Rajaei F, Teimoori-Toolabi L.
    Cancer Chemother Pharmacol; 2017 Oct 10; 80(4):765-775. PubMed ID: 28887583
    [Abstract] [Full Text] [Related]

  • 10. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
    Cioffi M, Trabulo SM, Sanchez-Ripoll Y, Miranda-Lorenzo I, Lonardo E, Dorado J, Reis Vieira C, Ramirez JC, Hidalgo M, Aicher A, Hahn S, Sainz B, Heeschen C.
    Gut; 2015 Dec 10; 64(12):1936-48. PubMed ID: 25887381
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
    Mittal A, Chitkara D, Behrman SW, Mahato RI.
    Biomaterials; 2014 Aug 10; 35(25):7077-87. PubMed ID: 24836307
    [Abstract] [Full Text] [Related]

  • 12. miRNA profiling in pancreatic cancer and restoration of chemosensitivity.
    Singh S, Chitkara D, Kumar V, Behrman SW, Mahato RI.
    Cancer Lett; 2013 Jul 01; 334(2):211-20. PubMed ID: 23073476
    [Abstract] [Full Text] [Related]

  • 13. Knockdown of TGF-β in Pancreatic Cancer Helps Ameliorate Gemcitabine Resistance.
    Wang X, Su W, Qin C, Gao R, Shao S, Xu X, Zhang Z, Gao J.
    Front Biosci (Landmark Ed); 2024 Jul 25; 29(7):269. PubMed ID: 39082329
    [Abstract] [Full Text] [Related]

  • 14. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
    Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S.
    PLoS One; 2011 Jul 25; 6(8):e24099. PubMed ID: 21909380
    [Abstract] [Full Text] [Related]

  • 15. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
    Tu MJ, Ho PY, Zhang QY, Jian C, Qiu JX, Kim EJ, Bold RJ, Gonzalez FJ, Bi H, Yu AM.
    Cancer Lett; 2019 Feb 01; 442():82-90. PubMed ID: 30389433
    [Abstract] [Full Text] [Related]

  • 16. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
    Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, Krebs S, Mysliwietz J, Jäckel C, Nelson PJ, Blum H, Jauch KW, Ellwart JW, Bruns CJ.
    Target Oncol; 2015 Jun 01; 10(2):215-27. PubMed ID: 24950733
    [Abstract] [Full Text] [Related]

  • 17. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y, Li K, Tao X, Zhao Y, Chen Q, Li N, Liu J, Go VLW, Guo J, Gao G, Xiao GG.
    Pancreas; 2021 Oct 01; 50(9):1260-1266. PubMed ID: 34860809
    [Abstract] [Full Text] [Related]

  • 18. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
    Shi Y, Wang Y, Qian J, Yan X, Han Y, Yao N, Ma J.
    Life Sci; 2020 Oct 15; 259():118148. PubMed ID: 32721465
    [Abstract] [Full Text] [Related]

  • 19. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
    Duong HQ, Hwang JS, Kim HJ, Kang HJ, Seong YS, Bae I.
    Int J Oncol; 2012 Sep 15; 41(3):855-61. PubMed ID: 22710732
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
    Morimoto M, Matsuo Y, Koide S, Tsuboi K, Shamoto T, Sato T, Saito K, Takahashi H, Takeyama H.
    BMC Cancer; 2016 May 12; 16():305. PubMed ID: 27175473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.